Changes in Hemoglobin Level Distribution in US Dialysis Patients From June 2006 to November 2008
Background
Erythropoiesis-stimulating agents (ESAs) have had a positive effect on anemia treatment in dialysis patients. However, several events in recent years, including new clinical study results, ESA product label revisions, and coverage and reimbursement policy changes, have had an impact on ESA dosing patterns and consequently on hemoglobin (Hb) distribution characteristics in this patient population.
Study Design
Retrospective observational study using patient-level data from ∼87% of dialysis centers in the United States.
Setting & Participants
Dialysis patients who were receiving outpatient care at dialysis facilities during June 2006-November 2008 were included in this study.
Predictor
Recent events affecting ESA treatment practice patterns in US dialysis patients.
Outcomes & Measurements
Hb level distribution.
Results
Mean Hb level decreased by 0.37 g/dL during the indicated period. Additionally, standard deviation (SD) of the Hb level distribution decreased by 0.14 g/dL and skewness increased by −0.10. Hb measurements in specific ranges changed as follows: >12 g/dL, decreased by 11.3 percentage points;10-12 g/dL, increased by 9.4 percentage points; and <10 g/dL, increased by 1.9 percentage points. The percentage of patients with Hb level >13 g/dL for ≥3 months decreased by 2.9 percentage points.
Limitations
Potential bias in dialysis center selection and lack of information for patient characteristics.
Conclusions
Recent events affecting ESA use in dialysis patients have had the desired effect of increasing the proportion of Hb measurements within the US Food and Drug Administration recommended target range of 10-12 g/dL and decreasing the proportion of Hb measurements >12 g/dL. However, the proportion of Hb measurements <10 g/dL also has increased. Benefits of a decrease in Hb measurements in the >12 g/dL range need to be considered, together with risks of having low Hb levels.
Index Words: Hemoglobin (Hb) distribution, dialysis, erythropoiesis-stimulating agents, Hb standard deviation
To access this article, please choose from the options below
Originally published online as doi:10.1053/j.ajkd.2009.09.024 on November 23, 2009.
PII: S0272-6386(09)01310-9
doi:10.1053/j.ajkd.2009.09.024
© 2009 National Kidney Foundation, Inc. Published by Elsevier Inc All rights reserved.
